Journal of International Psychiatry

Abstract Objective: To investigate the effect of Madopar and selegiline treatment in patients with Parkinsons disease clinical effect and its safety evaluation. Methods: 86 cases of primary Parkinsons disease in our hospital during the period from August 2014 to August 2015, according to the random number table method were randomly divided into observation group 43 cases and control group 43 cases. Observation group were treated with Madopar and selegiline treatment, control group only with madopar. Two groups of treatment were 3 months. The therapeutic effect of the two groups were compared before and after treatment, the modified Webster symptom scale score, MDRSPD score and adverse drug reaction. Results: the total effective rate of the observation group (86.05%) was higher than that of the control group (67.44%) (P<0.05); Two groups of Webster score after treatment significantly reduced (P<0.05); observation group Webster score of treatment were lower than those in the control group (P<0.05); two groups MDRSPD score in the treatment significantly decreased (P<0.05); observation group treated with MDRSPD score lower than the control group (P<0.05); two groups had no serious with adverse drug reactions. No serious adverse drug reactions were found in the two groups. Conclusion: Madopar and our to Gilan treatment in patients with Parkinsons disease clinical effect is remarkable, and is safe and reliable, with important research value.

Keywords: Madopar; selegiline; Parkinson disease; clinical effect; safety